Literature DB >> 1895163

Brain lesions following combined treatment with methotrexate and craniospinal irradiation.

F F Cruz-Sanchez1, J Artigas, J Cervos-Navarro, M L Rossi, R Ferszt.   

Abstract

Eight patients with meningeal seeding by carcinoma or lymphomas were treated with intravenous (i.v.) and/or intrathecal (i.th.) Methotrexate (MTX). Seven patients received additional craniospinal irradiation and in all seven a fatal encephalopathy developed. On the bases of clinical and morphological findings we identified an acute and a delayed form of encephalopathy and concluded that the concurrent administration of Methotrexate and of craniospinal irradiation increases considerably the risk of brain damage.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1895163     DOI： 10.1007/bf00146878

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  24 in total

1.  Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation.

Authors:  P Livrea; M Trojano; I L Simone; G B Zimatore; G C Logroscino; L Pisicchio; G Lojacono; R Colella; A Ceci
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

2.  Proceedings: Parenchymatous degeneration of the central nervous system in childhood leukemia.

Authors:  B Hendin; D C DeVivo; R Torack; M E Lell; A H Ragab; T J Vietti
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

3.  Transport of methotrexate by the choroid plexus.

Authors:  R Rubin; E Owens; D Rall
Journal:  Cancer Res       Date:  1968-04       Impact factor: 12.701

4.  [Neurotoxicity of intrathecal methotrexate administration and external meningoencephalic irradiation in carcinomatous meningitis. Must one reconsider therapeutic technics for meningitis in acute lymphoblastic leukemias and non-Hodgkin's lymphomas?].

Authors:  E Touboul; F Fauchon; H Merle-Béral
Journal:  Nouv Rev Fr Hematol       Date:  1981

5.  Necrotizing leukoencephalopathy and treated multiple myeloma. An autopsy case without intrathecal chemotherapy or irradiation of the brain.

Authors:  T Mizutani; Y Morimatsu; K Hayakawa
Journal:  Acta Pathol Jpn       Date:  1984-05

6.  Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma.

Authors:  B W Ongerboer de Visser; R Somers; W H Nooyen; P van Heerde; A A Hart; J G McVie
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

7.  Response of astrocytoma to high-dose methotrexate with citrovorum factor rescue.

Authors:  I Djerassi; J S Kim; A Reggev
Journal:  Cancer       Date:  1985-06-15       Impact factor: 6.860

8.  Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia.

Authors:  A W Craft; H Kay; D N Lawson; T J McElwain
Journal:  Br Med J       Date:  1977-12-10

9.  Leukoencephalopathy in childhood leukemia.

Authors:  D C Devivo; D Malas; J S Nelson; V J Land
Journal:  Neurology       Date:  1977-07       Impact factor: 9.910

10.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.

Authors:  W R Wasserstrom; J P Glass; J B Posner
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860
View more
  4 in total

1.  Primary Central Nervous System Lymphoma.

Authors:  Denise M. Damek
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 2.  Neurologic sequelae of treatment of primary CNS lymphomas.

Authors:  U Schlegel; H Pels; R Oehring; I Blümcke
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 3.  Chemotherapy and the pediatric brain.

Authors:  Chrysanthy Ikonomidou
Journal:  Mol Cell Pediatr       Date:  2018-11-06

4.  Cognitive function of children and adolescent survivors of acute lymphoblastic leukemia: A meta-analysis.

Authors:  Kalliopi Mavrea; Vasiliki Efthymiou; Katerina Katsibardi; Konstantinos Tsarouhas; Christina Kanaka-Gantenbein; Demetrios A Spandidos; George Chrousos; Antonis Kattamis; Flora Bacopoulou
Journal:  Oncol Lett       Date:  2021-02-05       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.